Bicycle Therapeutics (BCYC) Non-Current Deferred Tax Liability (2022 - 2023)
Bicycle Therapeutics' (BCYC) quarterly Non-Current Deferred Tax Liability came in at $3.4 million in Q4 2023, down 23.1% YoY from $4.4 million in Q4 2022, and down 23.1% on a QoQ basis from $4.4 million in Q4 2022.
Powered by 
Analysis
Bicycle Therapeutics (BCYC) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Bicycle Therapeutics (BCYC) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $3.4 million in Q4 2023.
- Quarterly Non-Current Deferred Tax Liability fell 23.1% year-over-year to $3.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3.4 million (down 23.1% YoY) and the FY2023 annual result came in at $3.4 million, down 23.1% from the prior year.
- Non-Current Deferred Tax Liability declined to $3.4 million in Q4 2023, from $4.4 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $4.4 million in Q4 2022 to a low of $3.4 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Bicycle Therapeutics | 299.81 Mn | 299.81 Mn | - |